Still on track:
"Response Biomedical Reaffirms Commitment To Hitting Milestones At AGM
VANCOUVER, BRITISH COLUMBIA--Response Biomedical Corp. (RBM:CDNX) held its Annual General Meeting yesterday, where the Company's commitment to meeting its development and operational timelines was reaffirmed.
``Since completing development of the RAMP diagnostic platform late last year, we have moved swiftly to carry out our first multi-center human clinical trial. Results of the RAMP Reader and myoglobin cardiac marker trials are on schedule to be submitted to the FDA for clearance in accordance with our June 30 timeline'', stated President & CEO, Bill Radvak. ``The Company is focused on completing additional RAMP tests and acquiring regulatory clearances in a timely fashion that will allow the RAMP System to be marketed in North America and Europe next year.''
At the meeting, Mr. Radvak and the Company's Senior Management provided details of recent business development accomplishments, R&D progress, clinical trials, and the newly established Scientific Advisory Board (``SAB''). The SAB is chaired by University of Maryland Professor of Pathology and Director of Point-of-Care Testing, Dr. Robert Christenson and includes former AACC President and Loyola University Professor, Dr. Stephen Kahn, and Chief of Cardiology and UNC Professor of Medicine, Dr. Magnus Ohman. The internationally renowned members of the SAB will advise management on clinical issues as the Company moves toward FDA clearance of its RAMP cardiac tests. Additionally, the SAB will provide input on the development of new RAMP tests and new diagnostic technologies.
Vice President of R&D, Dr. Paul Harris, reported that the Company's CK-MB and troponin I cardiac assays, which will be marketed along with the myoglobin blood test, were on schedule to enter clinical trials late this year. He also reported that the RAMP PSA test being developed for Japan's Nippon Kayaku Co. Ltd., was moving well through the development program and that early results were positive.
All resolutions presented at the AGM were approved, including the re-election of the Company's Board of Directors. Following the meeting, interim Chairman John Hayes resigned his Board seat citing personal reasons. Bill Radvak commented, ``I would like to personally thank John for his valuable contribution during his tenure as a director. He has supported us since 1992 and on behalf of everyone at Response Biomedical, I wish him well in his retirement.'' |
